This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).

NCT ID: NCT03539926

Last Updated: 2018-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-09

Study Completion Date

2019-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the superiority of daily self-pH monitorization of Lit-control®pH meter compared to the monitorization of reactive strips (standard of care).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cystinuria is a disease of autosomal recessive inheritance. This disease belongs to the so-called orphan diseases although its prevalence may change depending on the country.

It is known that urinary pH is a risk factor for the formation of cystine crystals because their solubility is pH-dependent. In different studies it has been shown that the solubility of cystine in urine increases when alkalinizing urinary pH, thus reducing the likelihood of crystal formation. Therefore, the control of urinary pH along with hygienic-dietetic measures that alkalize the urine or decrease the urinary concentration of cystine (abundant intake of water, food, etc.) are highly recommended as a preventive method to prevent the formation of cystine crystals whose retention and growth results in the formation of stones.

The Lit-control®pH Meter is a pH meter that allows a patient to self-monitor its urinary pH in a comfortable and simple way. With this tool the patient is able to know if his urinary pH is within the recommended limits. In other medical fields it has been observed that home monitoring of clinically relevant physiological parameters is a way of empowering the patient that can positively affect their attitudes and behaviors (adherence to received treatment, quality of life) and potentially improve their medical condition. Specifically, in patients with chronic diseases, the self-monitoring has been associated with a significant reduction in hospitalizations and hospital readmissions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystinuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will receive the product for home pH monitoring, but they will keep following the doctor's recommendations indicated in the usual clinical practice.

The proportion of patients will be 1: 1 between the study group (Lit-control®pH Meter) and the control group (test strips).
Primary Study Purpose

OTHER

Blinding Strategy

NONE

The process of randomization, either device use or use of strips, will be masked until the moment it is delivered to the patient. The random assignment to each product will be made through lists created by an ad hoc computer program.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lit-control®pH Meter

The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.

Group Type EXPERIMENTAL

Lit-control®pH Meter

Intervention Type DEVICE

Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.

Reactive strips

The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.

Group Type PLACEBO_COMPARATOR

Reactive strips

Intervention Type DIAGNOSTIC_TEST

Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lit-control®pH Meter

Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.

Intervention Type DEVICE

Reactive strips

Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years old.
* Cystinuric patients, with or without urinary lithiasis at the time of inclusion.
* Patients who accept their participation in the study and give their informed consent.

Exclusion Criteria

* Patients with pathologies that require pH control other than the one established in the study protocol to avoid the formation of kidney stones.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clever Instruments S.L.

INDUSTRY

Sponsor Role collaborator

Fundacio Puigvert

OTHER

Sponsor Role collaborator

Devicare S.L.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Oriol Angerri, MD

Role: PRINCIPAL_INVESTIGATOR

Fundacio Puigvert

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundacio Puigvert

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DEV-LCD-01-17

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Interstitial Cystitis
NCT00056251 COMPLETED PHASE2
Urine Alkalinization for UTI in Women: RCT
NCT07202832 NOT_YET_RECRUITING NA